Transforming growth factor-beta: a local or systemic mediator of plaque stability?
Lutgens
E
E
Daemen
M J
MJ
D000818:Animals; D001057:Apolipoproteins E / Q000172:deficiency / Q000235:genetics; D001161:Arteriosclerosis / Q000150:complications / Q000276:immunology / Q000503:physiopathology*; D019013:CD40 Antigens / Q000378:metabolism; D023201:CD40 Ligand / Q000378:metabolism; D004195:Disease Models, Animal; D018450:Disease Progression; D006801:Humans; D007141:Immunoglobulin Fc Fragments / Q000235:genetics; D007249:Inflammation / Q000150:complications / Q000276:immunology / Q000503:physiopathology; D008264:Macrophages / Q000276:immunology; D051379:Mice; D018345:Mice, Knockout; D017346:Protein Serine-Threonine Kinases; D000077294:Receptor, Transforming Growth Factor-beta Type II; D018125:Receptors, Transforming Growth Factor beta / Q000008:administration & dosage / Q000235:genetics; D011993:Recombinant Fusion Proteins / Q000008:administration & dosage / Q000235:genetics; D015398:Signal Transduction / Q000187:drug effects; D013601:T-Lymphocytes / Q000276:immunology; D016212:Transforming Growth Factor beta / Q000037:antagonists & inhibitors / Q000235:genetics / Q000378:metabolism*
D001057:Apolipoproteins E; D019013:CD40 Antigens; D007141:Immunoglobulin Fc Fragments; D018125:Receptors, Transforming Growth Factor beta; D011993:Recombinant Fusion Proteins; D016212:Transforming Growth Factor beta; D023201:CD40 Ligand; D017346:Protein Serine-Threonine Kinases; D000077294:Receptor, Transforming Growth Factor-beta Type II